Synthesis and Evaluation of New HCV NS3/4A Protease Inhibitors by Koumbaros, Evangelos Konstantinos
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
April 2013
Synthesis and Evaluation of New HCV NS3/4A
Protease Inhibitors
Evangelos Konstantinos Koumbaros
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Koumbaros, E. K. (2013). Synthesis and Evaluation of New HCV NS3/4A Protease Inhibitors. Retrieved from
https://digitalcommons.wpi.edu/mqp-all/2441
                       
 
 
Synthesis and Evaluation of New HCV NS3/4A Protease Inhibitors 
 
 
A Major Qualifying Project Report: 
Submitted to the Faculty  
Of  
WORCESTER POLYTECHNIC INSTITUTE  
In partial fulfillment of the requirements for the  
Degree of Bachelor of Science 
By: 
______________________ 
Evangelos Koumbaros 
Advisor 
Destin Heilman 
In Cooperation with 
Akbar Ali, Ph.D. 
UMass Medical School 
 
 
 
Table of Contents 
Acknowledgments ..................................................................................................................................... 4 
Abstract ..................................................................................................................................................... 5 
Background ............................................................................................................................................... 6 
Protease Inhibitors ................................................................................................................................ 8 
Telaprevir .............................................................................................................................................. 8 
Boceprevir ............................................................................................................................................. 9 
MK-5172 ............................................................................................................................................... 9 
Methods .................................................................................................................................................. 11 
Results ..................................................................................................................................................... 23 
Evaluation of the Synthesis ................................................................................................................. 23 
NMR ................................................................................................................................................... 24 
Conclusions ............................................................................................................................................. 26 
References ............................................................................................................................................... 28 
Figures .................................................................................................................................................... 29 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Figures 
Figure 1 ....................................................................................................................................................... 29 
Figure 2 ....................................................................................................................................................... 29 
Figure 3 ....................................................................................................................................................... 30 
Figure 4 ....................................................................................................................................................... 30 
Figure 5 ....................................................................................................................................................... 31 
Figure 6 ....................................................................................................................................................... 31 
Figure 7 ....................................................................................................................................................... 32 
Figure 8 ....................................................................................................................................................... 33 
Figure 9 ....................................................................................................................................................... 34 
Figure 10 ..................................................................................................................................................... 35 
Figure 11 ..................................................................................................................................................... 36 
Figure 12 ..................................................................................................................................................... 37 
Figure 13 ..................................................................................................................................................... 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgments 
 The successful completion of this Major Qualifying Project was possible with the help 
and support provided by many contributors. I would first like to thank Celia Schiffer for allowing 
me to work in her lab and participate in this incredible research. Second I would like to thank 
Akbar Ali. Without his guidance throughout this past year this project would not have been 
possible, and I am extremely grateful for all of his help. I would also like to thank Muhammad 
Jahangir for providing assistance and advice throughout the year. Finally I would like to thank 
Destin Heilman for his excellent advising and help with this project. This project and the 
research being done by the UMass lab have provided me with an incredible experience that has 
helped me grow as an individual. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract  
 The Hepatitis C virus infects an estimated 170 million people worldwide, and is the 
major cause of hepatitis, cirrhosis and liver cancer. The available treatment is a combination 
therapy with two non-specific antiviral agents, pegylated interferon (Peg-IFN) and ribavirin 
(RBV), which is effective for only half of the treated patients and has severe side effects. Recent 
addition of HCV NS3/4A protease inhibitors, Telaprevir and Boceprevir, to the therapy has 
improved HCV treatment outcomes. However, the severe side effects associated with Peg-
IFN/RBV and the rapid emergence of drug resistance against protease inhibitors limit the 
effectiveness of this new therapy. In addition, the new therapies are mostly developed for 
genotype 1 patients, and may not be affective against other genotypes. Therefore, new HCV 
therapies must be developed that are effective against a broader spectrum of resistant viral 
variants and HCV genotypes. This project involved following the multi-step synthesis of a new 
HCV NS3/4A protease inhibitor, MK-5172, evaluated the synthesis plan, and provided the 
University of Massachusetts Medical School with a new variant to test activity in biochemical 
assays against wild-type and drug resistant NS3/4A protease variants. 
 
 
 
 
 
 
 
Background  
Hepatitis C continues to affect 170 million people worldwide; nearly 3% of the global 
population. This disease develops from an infection of the Hepatitis C Virus (HCV), and 
primarily attacks and inflames the liver.  While some treatments have become available, there is 
no vaccine yet that can combat this disease that affects both humans and chimpanzees. Chronic 
HCV infections lead to cirrhosis, as well as liver failure or liver cancer. Hepatitis C accounts for 
30-40% of orthotopic liver transplants in many western countries,1 and results in an estimated 
476,000 deaths annually as a result of end-stage liver disease and its complications.2  
The spread of Hepatitis C has increased in the 20th century, and about 4 million people 
are infected each year.3 This is primarily due to unsafe and unclean medical practices and 
equipment, which is also a factor in the spread of HCV by intravenous drug use and needle 
sharing. However, this is not the only way to transmit the virus. As seen in Figure 1, drug use 
only accounts for about 60% of the continued spread.4 HCV screenings for blood used in 
transfusions and organs for transplants have not always been performed, and are still not done in 
some countries due to the cost. The requiring of these screenings in 1992 by the United States 
reduced the risk of infection from 1 in 200 to 1 in 10,000,000 per unit of blood,5 but there was 
still a great for risk anyone who received a blood transfusion prior. HCV is also believed to be 
spread through sexual intercourse, but that remains a controversial subject. An association 
between infections and high-risk sexual behavior exists, but that may “be because of a high rate 
of sexual transmission or… unacknowledged drug use.”4 Other ways to transmit the virus include 
body tattoos and piercings, due to unclean needles or contaminated dyes, and vertical 
transmission from mother to fetus.   
The map shown in Figure 2 shows the major areas of the globe that are affected by HCV. 
It is easy to spot the high and low prevalence areas; for example about 2% of residents in 
countries like the US, Australia, Spain, and Japan are infected. That number has decreased over 
the past years because of improved screenings of blood and organs before use. The greatest 
prevalence of HCV is in Egypt, and certain areas of the country have reported infection rates as 
high as 24% of the local population.3  
The Hepatitis C Virus, discovered in 1989, is a member of the Flaviviridae family of 
viruses, and the Hepacivirus genus. The virus’ structure is an enveloped, positive single-stranded 
RNA molecule 9.6 kilobases long, and encodes about 3,000 amino acids. The virus generates 10 
viral proteins: the viral core, Envelope 1 (E1), E2, p7, and nonstructural (NS) 2, NS3, NS4A and 
NS4B, and NS5A and NS5B.6 These proteins spread the virus throughout the host, and also 
affect different cellular functions. HCV has nine major genotypes, numbered one through nine, 
but to date more than 30 have been identified. Genotype 1 accounts for 72% of cases worldwide, 
Genotype 2 accounts for 16-19%, 8-10% for Genotype 3, and 1-2% for the remaining.7 Apart 
from the United States, Genotype 1 is also the most common is South America and Europe.8 The 
virus can remain dormant for decades after initial infection, and when active primarily causes 
cirrhosis and liver cancer.3 About 15% of those infected by HCV develop acute symptoms, and 
80% of cases develop chronic infections.  
Current HCV treatments aim to slow the progression of the virus, as well as preventing 
cirrhosis and other symptoms from developing, and have been found to clear as high as 80% of 
chronically infected persons.9 However the treatments vary by genotype, and new ones focus 
mainly on Genotype 1, which may not be effective when treating any of the others. The 
recommended treatment for Genotype 1 lasts as long as 48 weeks, and patients are required to 
take 1000mg ribavirin (RBV) daily if they are 75kg or less, and 1200mg daily if their weight is 
greater than 75kg. Pegylated interferon α-2a or 2b (PEG-IFN-α), a 165 amino acid pegylated 
interferon, is also administered intravenously, and helps trigger cell immune responses. The viral 
responses to these treatments are about 45-50% for Genotype 1, and with slight alterations to 
RBV quantities for Genotypes 2-4 the response is 70-80%.4   
Protease Inhibitors  
 Protease inhibitors are drugs that are used to treat and prevent viral infections such as the 
Hepatitis C Virus and HIV. These inhibitors work by binding to and inhibiting the activity of 
enzyme proteases, and have proven to be effective an effective method at treating viral 
infections. Specifically, HCV inhibitors target the NS3 and NS4A proteases, as they are essential 
for viral replication and circumventing the host immune response.  
There are a number of protease inhibitors in development, seen in Figure 3, and two have 
already been approved by the FDA for adult Hepatitis C treatment; Telaprevir and Boceprevir. 
They are both from a class of keto-amide compounds that target and bind to the active site serine, 
and are used in addition to RBV and PEG-IFN-α therapy. However, the severe side effects 
associated with PEG-IFN-α/RBV, and the rapid emergence of drug resistance against protease 
inhibitors limit the effectiveness of this new triple combination therapy. 
Telaprevir  
 Telaprevir, C36H53N7O6, is a drug developed by Vertex and Johnson & Johnson used to 
treat Hepatitis C. The compound is in the class of protease inhibitors and specifically binds and 
inhibits the NS3 and NS4A serine proteases. Seen in Figure 3, the drug has only been found to be 
effective on Genotype 1. Due to the lower responses from current therapies on this genotype, it is 
a great addition to treating the virus. The most common side effect of the drug is a rash, which 
during testing occurred in 51% of patients, and 5% developed a severe case.10 
Boceprevir  
 Boceprevir, C27H45N5O5, is another protease inhibitor used to treat HCV Genotype 1. It 
also targets and binds to the NS3 active site.11 Shown by Figure 3, and marketed as Victrelis, it is 
being developed by Merck, and has been approved by the FDA for oral use after 4 weeks of 
regular PEG-IFN-α/RBV treatments. It has more noted side effects than Telaprevir, which 
include nausea, hair loss, and rash outbreaks. Boceprevir has also been found to cause more 
severe effects like fainting, dizziness, shortness of breath, and patients can exhibit possible signs 
of infections.12 
MK-5172  
 One of the drugs currently in development is the MK-5172 inhibitor, seen in Figure 3, 
and was the compound focused on for this project. It is a non-covalent acyl sulfonamide inhibitor 
and contains P2–P4 macrocycles. Within each inhibitor series of same P2 moiety, the drug 
resistance profiles are similar, indicating that the identity of P2 moiety largely determines 
susceptibility to drug resistance. The P2–P4 macrocyclic inhibitors also display higher fold-
losses. 13 Unlike other inhibitors, MK-5172 contains a short ether linkage between its P2 proline 
and the quinoxaline moiety, which can be seen in Figure 4, and past studies have shown that 
MK-5172 retains relatively better potency against HCV. Both the linear and P1–P3 macrocyclic 
analogues of MK-5172 retain better potency against drug resistant variants compared to the 
original drug structure. The research conducted for this drug attempt to decrease it in size, in 
order to better fit the substrate the envelope and increase its overall effectiveness. These results 
suggest that even in the absence of P2–P4 macrocycle, the P2 quinoxaline moiety maintains the 
unique binding conformation observed for MK-5172. 13 The linear structure, seen in Figure 5, 
was the focus for this synthesis. 
Combatting HCV’s rapid mutation and drug resistance rates is necessary when 
researching new drugs and treatments, so further development of these compounds and 
treatments is essential. The introduction of new protease inhibitors to the PEG-IFN-α/RBV 
therapy may also increase effectiveness against the varying genotypes of HCV, which make it 
difficult to treat. This research will also allow for better managing the severe side effects and 
symptoms caused by HCV and its treatments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods  
This section details the synthesis of the NS3/4A inhibitor derivative in Figure 6. All 
reactions were carried out in standard glassware. When purifying with column chromatography, 
unless otherwise stated thin layer chromatography (TLC) tests were run in 30% EtOAc in 
hexanes. Nuclear Magnetic Resonance (NMR) tests were run at 400 MHz and the solvents were 
CDCl3. Chemical shift multiplicity data are presented as follows: s = singlet, d = doublet, dd = 
doublet of doublet, t = triplet, q =quartet, m = multiplet. Ethyl acetate is abbreviated EtOAc; 4-
Dimethylaminopyridine is abbreviated DMAP; N-Methyl-2-pyrrolidone is abbreviated NMP; 
Dimethylformamide is abbreviated DMF; (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate) is abbreviated HATU; N,N-Diisopropylethylamine is 
abbreviated DIEA; Diethyl ether is abbreviated Et2O. 
1. (2R,4S)-1-tert-butyl 2-methyl 4-(((4-bromophenyl)sulfonyl)oxy)pyrrolidine-1,2-
dicarboxylate 
 
A solution of N-Boc-cis-4-hydroxy-L-proline methyl ester (10.17g, 41.4 mmol) in dry 
CH2Cl2 (70 mL) was cooled to 0 oC and Et3N (28.7 mL, 205.8 mmol) was slowly added. After 15 
minutes, solid 4-bromobenzesulfonyl chloride (21.16g, 82.8 mmol) was added, followed by the 
addition of DMAP (.3 g, cat.). The reaction mixture was stirred at 0 oC for 30 minutes and then 
stored in a refrigerator (5 oC) for 24 hours. The reaction mixture was slowly warmed to room 
temperature (ice water, cold water, water, and then RT), diluted with CH2Cl2 (200 mL), and 
washed with saturated aqueous NaHCO3 solution (100 mL) and 10% aqueous citric acid solution 
(100 mL). The organic portion was dried (Na2SO4) and evaporated under reduced pressure. The 
residue was purified by flash column chromatography, eluting with 2-4% EtOAc in CH2Cl2 
mixture to yield a light yellow gummy solid (16.35 g), which solidified on standing in a 
refrigerator. 
2. (2R,4R)-1-tert-butyl 2-methyl 4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-
1,2-dicarboxylate 
 
To an ice-cooled solution of 3-chloro-7-methoxyquinoxalin-2-ol (1g, 4.75 mmol) in NMP 
(15 mL), Cs2CO3 (2.32g, 7.12 mmol) was added under nitrogen atmosphere. The reaction 
mixture was stirred at 0 oC for 15 minutes, warmed to 15 oC and treated with solid bosylated-cis 
proline-OMe (2.2 g, 4.75 mmol). The resulting mixture was stirred at room temperature for 30 
minutes, heated to 50 oC and stirred overnight. The reaction mixture was cooled to room 
temperature, diluted with EtOAc (150 mL) and H2O (50 mL) and layers were separated. The 
organic portion was washed with aqueous 1N HCL solution (50 mL), saturated aqueous NaHCO3 
solution (50 mL) and saturated aqueous NaCl solution (50 mL). The organic portion was dried 
(Na2SO4), filtered and evaporated to dryness under reduced pressure. The residue was purified 
by flash column chromatography, using 15-20% EtOAc in hexanes as eluent, to provide the 
desired product (.58g) as a pale yellow foamy solid. 
 
3. (2S,4R)-Methyl 4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate 
hydrochloride 
 
To a solution of proline derivative (2R,4R)-1-tert-butyl 2-methyl 4-((3-chloro-7-
methoxyquinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate (.58g, 1.32 mmol) in anhydrous 
CH2Cl2 was added a solution of 4N HCL in dioxane and the mixture was stirred at room 
temperature overnight. Solvents were removed by rotary evaporation and the residue was dried 
under high vacuum. The solid residue was washed with THF (10 mL), then triturated with 
anhydrous Et2O (30 mL), transferred, washed with Et2O (2 x 10 mL), and dried under high 
vacuum to provide the product (.48 g, 97%) as a pale yellow solid.  
4. (2S,4R)-Methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-((3-
chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate 
 A mixture of proline derivative (2S,4R)-Methyl 4-((3-chloro-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidine-2-carboxylate hydrochloride (.48g, 1.28 mmol) and Boc-Tle-OH (.38g, 1.66 
mmol, 1.3 eq) in dry DMF(10 mL) was cooled to 0 oC under a dry nitrogen atmosphere. DIEA 
(1.3 mL, 7.68 mmol, 6.0 eq) was added and the mixture was stirred at 0 oC for 15 minutes. Solid 
HATU (.73g, 1.94 mmol, 1.5 eq) was added and after 15 minutes the reaction mixture was 
warmed to room temperature and stirred overnight. The reaction mixture was diluted with EtOAc 
(150 mL) and washed with aqueous 1N HCL solution (40 mL), saturated aqueous NaHCO3 
solution (40 mL), and saturated aqueous NaCl (40 mL). The organic portion was dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The residue was purified by flash column 
chromatography, using 20% EtOAc in hexanes as eluent, to provide the desired product (.38g, 
54%) as an off-white foamy solid.  
5. (2S,4R)-Methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-((7-
methoxy-3-vinylquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate 
 To a solution of the above intermediate (.38g, .69 mmol) in EtOH (15 mL) was added 
solid potassium vinyltrifluoroborate (.14g, 1.035 mmol, 1.3 eq) at room temperature. The 
reaction vessel was filled with dry N2 and Et3N (.105 mL, 1.04 mmol) was slowly added. Dry N2 
was bubbled through the reaction mixture for 10 minutes, then catalyst PdCl2(dppf)-CH2Cl2 
(.06g, .07 mmol) was added, and the reaction mixture was heated at 80 oC for 2 hours. Reaction 
mixture was cooled to room temperature, diluted with H2O (40 mL) and EtOAc (100 mL) and 
layers were separated. The organic portion was washed with H2O (40 mL) and saturated aqueous 
NaCl solution (40 mL), dried (Na2SO4), filtered, and evaporated under reduced pressure. The 
residue was purified by flash column chromatography, using 20% EtOAc in hexanes as eluent, to 
provide the desired product (.03g, 10%) as an orange gummy solid. 
6. (2S,4R)-Methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-((3-ethyl-
7-methoxyquinoxalin-2-yl)-oxy)pyrrolidine-2-carboxylate 
 The above compound (.87 g) was dissolved in a mixture of MeOH-1,4-dioxane (14 mL, 
1:1), and the solution was degassed using a vacuum and was filled with dry N2 (three cycles). 
Pd/C (212 mg) was added, and the degassing process was repeated for another three cycles. The 
reaction was degassed a final time and then filled with Hydrogen using three large balloons, and 
left to stir overnight. The solution was filtered by vacuum filtration through Celite, which was 
thoroughly washed with Methanol and Ethyl Acetate. It was then evaporated under reduced 
pressure and purified by flash column chromatography, using 25% EtOAc + .05% Et3N in 
hexanes as eluent, to provide the desired product (.51g, 59%)as a yellow foamy solid. 
7. (2S,4R)-Methyl 4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate 
hydrochloride 
  A solution of proline derivate (.18 g) in anhydrous CH2Cl2 (2-3 mL) was added to a 
solution of 4N HCl in dioxane (5 mL) and the mixture was stirred at room temperature for 6 
hours. Solvents were removed by rotary evaporation, and the residue was dried under high 
vacuum. It was then washed with THF and dried under high vacuum (2 x 5 mL), and was washed 
a final time with Et2O (5 mL) and dried to provide the product (.18 g, 100%)  as a pale yellow 
solid. 
8. (2S,4R)-Methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-((3-ethyl-
7-methoxyquinoxalin-2-yl)-oxy)pyrrolidine-2-carboxylate 
 
 A mixture of proline derivative (2S,4R)-Methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-
3,3-dimethylbutanoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)-oxy)pyrrolidine-2-carboxylate 
hydrochloride (.18g, .5 mmol) and Boc-Tle-OH (.16g, .7 mmol, 1.3 eq) in dry DMF(5 mL) was 
cooled to 0oC under a dry nitrogen atmosphere. DIEA (.53 mL, 3.03 mmol, 6.0 eq) was added 
and the mixture was stirred at 0 oC for 15 minutes. Solid HATU (.29g, .75 mmol, 1.5 eq) was 
added and after 15 minutes the reaction mixture was warmed to room temperature and stirred 
overnight. The reaction mixture was diluted with EtOAc (50 mL) and washed with aqueous 1N 
HCL solution (30 mL), saturated aqueous NaHCO3 solution (30 mL), and saturated aqueous 
NaCl (30 mL). All layers were rewashed with clean EtOAc (100 mL), and the organic portions 
were combined. The organic portion was dried (Na2SO4), filtered, and evaporated under reduced 
pressure. The residue was purified by flash column chromatography, using 20% EtOAc in 
hexanes as eluent, to provide the desired product (.14g, 81%) as a yellow foamy solid. 1H NMR 
(400 MHz,CDCl3) δ 8.87 (d, J=9.2 Hz, 1H), 7.19 (dd, J=8.8, 2.8 Hz, 1H) 7.13 (d, J=2.8 Hz, 1H), 
5.18 (d, J=9.2 Hz, 1H), 4.73 (t, J=8.4 Hz, 1H), 4.24 (m, 2H), 4.07 (m, 1H), 3.94 (s, 3H), 3.78 (s, 
3H), 2.89 (m, 2H), 2.68 (m, 1H), 2.35 (m, 1H), 1.33 (s, 9H), 1.27 (t, J=7.2 Hz, 1H), 1.05 (s, 9H), 
0.99 (s, 1H).  
9. (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-((3-ethyl-7-
methoxyquinoxalin-2-yl)-oxy)pyrrolidine-2-carboxylic acid 
 A solution of the above intermediate (.64g, 1.17 mmol) in H2O-THF (1:1) mixture (30 
mL) was treated with LiOH (.17g, 4.05 mmol), and the mixture was stirred at room temperature 
for 24 hours. The reaction mixture was acidified to pH 3.0 by slowly dripping aqueous .2N HCl, 
and was extracted with EtOAc (2 x 150 mL). The organic portion was washed with saturated 
aqueous NaCl solution (50 mL), dried (Na2SO4), filtered, and evaporated under reduced pressure. 
The residue was dried under high vacuum to provide the acid (.64g, 100%) as a clear gummy 
solid. It was used in the next coupling step.  
10. (1R,2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide 
hydrochloride  
 
A solution of the above intermediate (.5g, 1.51 mmol) in anhydrous CH2CL2 (5 mL) under dry 
N2 was treated with TFA (5 mL) and the resulting solution was stirred at room temperature for 1 
hour. After the solvents were evaporated under reduced pressure, the residue was treated with 
toluene (5 mL) and the solution was evaporated to dryness using high vacuum. The residue was 
then treated with 4N HCL in 1,4-dioxane (4 mL) and the solution was evaporated to dryness. The 
residue was dissolved in anhydrous THF (5 mL) and the solution was evaporated to dryness 
using high vacuum (2x) to provide the product (.5g, 100%) as a brown gummy solid.  
11. tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidin-1-yl)-
3,3-dimethyl-1-oxobutan-2-yl)carbamate (5172-linear) 
 
A solution of (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-((3-ethyl-
7-methoxyquinoxalin-2-yl)-oxy)pyrrolidine-2-carboxylic acid (.64g, 1.17 mmol) and (1R,2S)-1-
amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide hydrochloride (.5g, 1.35 
mmol) in CH2CL2-DMF (20 mL, 10:1 mixture) was cooled to 0 oC under a dry N2 atmosphere. 
DIEA (1.02 mL, 5.85 mmol) was slowly added, and after 15 minutes at 0 oC solid HATU (.67g, 
1.76 mmol) was added, followed by DMAP (.14g, 1.17 mmol). The resulting mixture was stirred 
for 15 minutes at 0 oC, warmed to room temperature, and stirred overnight. The solvents were 
partially evaporated under reduced pressure, and the residue was diluted with EtOAc (100 mL). 
The solution was washed with aqueous .5N HCL solution (35 mL), saturated aqueous NaHCO3 
(35 mL), and saturated aqueous NaCl solution (35 mL). The organic portion was dried 
(Na2SO4), filtered, and evaporated under reduced pressure. The residue was purified by flash 
column chromatography, using 50% EtOAc in hexanes as eluent, to provide the desired product 
(.5g) as a white solid. TLC tests were run in 65% EtOAc. 1H NMR (400 MHz,CDCl3) δ 10.08 (s, 
1H), 7.83 (d, J=9.2 Hz, 1H), 7.19 (dd, J=8.4,2.4 Hz, 1H), 7.14 (s, 1H), 7.07 (s, 1H), 5.90 (s br, 
1H), 5.76 (m, 1H), 5.28-5.22 (m, 2H), 5.14 (d, J=10.4 Hz, 1H), 4.84 (t, J=8.4 Hz, 1H), 4.30 (d, 
J=12 Hz, 1H), 4.25 (d, J=9.6 Hz, 1H), 4.04 (dd, J=11.6, 3.2 Hz, 1H), 3.94 (s, 3H), 2.94-2.83 (m, 
3H), 2.79 (s, 1H), 2.55 (m, 2H), 2.12 (q, J=17.2, 8.8 Hz, 2H), 1.97 (t, J=6.4 Hz, 1H), 1.47 (m, 
1H), 1.33 (m, 9H), 1.27 (t, J=7.2 Hz, 3H), 1.11-0.97 (m, 12H).  
12.  
 
A solution of tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidin-1-yl)-3,3-
dimethyl-1-oxobutan-2-yl)carbamate (.25g) in anhydrous CH2Cl2 (3 mL) was added to a solution 
of 4N HCl in dioxane (5 mL) and the mixture was stirred at room temperature overnight. The 
solvents were removed by rotary evaporation, and the residue was dried under high vacuum. It 
was then washed with THF and dried under high vacuum (2 x 5 mL), and was washed a final 
time with Et2O (5 mL) and dried to provide the product (.25 g, 100%) as a pale white solid. 
13. 
 
A solution of the above intermediate (.25g, 0.34 mmol) and the above dicarbamate (.082g, 1.35 
mmol) in anhydrous DMF (6 mL) was cooled to 0 oC under a dry N2 atmosphere. DIEA (0.35 
mL, 1.75 mmol) was slowly added, and after 15 minutes the resulting mixture was warmed to 
room temperature, and stirred overnight. The solvents were evaporated under reduced pressure 
and the residue was purified by flash column chromatography, using 50% EtOAc in hexanes as 
eluent, to provide the final product as a white solid. TLC tests were run in 65% EtOAc in 
hexanes. 1H NMR (400 MHz,CDCl3) δ  9.94 (s, 1H), 7.60 (d, J=9.2 Hz, 1H), 7.19 (s, 2H), 7.12 
(d, J=8.4, 2.4 Hz, 1H), 7.07 (s, 1H), 6.94 (s, 1H), 5.83 (s, 1H), 5.7 (q, J= 12 Hz, 4H), 5.22 (s, 
1H), 5.17 (t, J=9.2 Hz, 2H), 5.10 (d, J=10.4 Hz, 1H), 4.82 (q, J=8.8 Hz, 3H), 4.43 (t, J=16 Hz, 
2H), 4.22 (dd, J=11.6 Hz, 10 Hz, 1H), 3.99 (d, J=3.6 Hz, 1H), 3.87 (s, 3H), 2.85 (m, J=18, 5H), 
2.50 (m, J=25.6, 5H), 2.00 (dd, J=8.8 Hz, 1H) 1.91 (t, J=6.4 Hz, 2H), 1.50 (s, 1H), 1.29 (d, 1H), 
1.2 (t, J=14.8 Hz, 2H), 1.14 (dd, J=2.4 Hz, 3H) 0.96 (s, 12H). 
 
Results  
The Hepatitis C virus causes a range of symptoms, and the side effects from current 
treatment methods are equally severe. The development of new drugs is necessary because of 
HCV’s rapid mutation and drug resistance rates. The goal of this project was to successfully 
synthesize the linear structure of the 5172 NS3/4A inhibitor, seen in Figure 5. The targeted 
groups, marked “A” and “B” in the figure, were then modified from the original drug structure, 
seen in Figure 3, in an attempt to increase enzymatic activity and effectiveness. The structure of 
the new compound can be seen in Figure 6.  
Evaluation of the Synthesis  
The synthesis plan of the MK-5172 inhibitor was developed in order to produce the most 
efficient yields, and involves a series of steps to build the compound from a collection of smaller 
molecules. Building the molecule begins with the synthesis of the quinoxaline and proline 
moiety, and to provide a better product yield in step 1, the 3-chloro-7-methoxyquinoxalin-2-ol 
was purchased from an outside company, instead of being synthesized in the lab. As expected, 
this compound provided a greater yield than previous experiments where the compound had been 
made on site. Beginning with these steps builds the compound while keeping the product yields 
consistent for the Boc removal in step 3, and the coupling in step 4.The purification process of 
step 4 resulted in an unusually low yield, and but still provided enough product to continue. A 
challenging part of the compound synthesis came between steps 5 and 6. The structure and 
instability of the product from 5 was observed as the yield dropped significantly after the 
compound was stored at 4 oC for 10-12 days. The following step 6 gave an extremely low 
product yield, approximately 10%, confirming the decomposition, and was not enough to 
continue to the next step in the synthesis. To obtain more of the product (2S,4R)-Methyl 1-((S)-2-
((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)-
oxy)pyrrolidine-2-carboxylate, the steps seen in steps 7 and 8 were taken, due to the availability 
of the starting material in 7. These reactions were carried out in order to attain enough of the 
(2S,4R)-Methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-((3-ethyl-7-
methoxyquinoxalin-2-yl)-oxy)pyrrolidine-2-carboxylate to use in experiment 9.Steps 7 and 8 
provided better yields than the reactions in steps 3 and 4, and after discussing these results with 
Dr. Ali, it was confirmed that they are consistently higher when the group on the quinoxaline 
moiety was an ethyl instead of the chlorine before the removal of the Boc group and addition of 
the Boc-Tle-OH. To get a good yield with a sample less than 300 mg in steps 7 and 3, the 
trituration and transfer with Et2O is left out, and the workup follows the procedure as written in 
step 7. The availability of the compounds in step 10 and 12 are a factor in the total synthesis 
plan, as they are necessary for the completion of the molecule. Overall each step in the synthesis 
provided the expected products, and produced 500 mg of a new derivative of the MK-5172 
inhibitor.  
NMR  
 In order to ensure the structure of the product for each reaction, Proton Nuclear Magnetic 
Resonance (NMR) tests were run following the completion of each step in the synthesis. These 
tests detect the presence of 1H protons, and measure their absorption of electromagnetic 
radiation. The spectrum it produces shows peaks based on the locations of these protons on the 
molecule, as well as their relative locations to other protons. The analysis of the NMR spectra for 
the final product is detailed below, and all of the spectra for the products obtained throughout the 
synthesis can be seen in Figures 7-13. These tests were used to verify that the desired compounds 
had been made in each step before moving on, as well as confirming the structure of the final 
compound.  
 The analysis of the final product synthesized is detailed below:  
1H NMR (400 MHz,CDCl3) δ  9.94 (s, 1H), 7.60 (d, J=9.2 Hz, 1H), 7.19 (s, 2H), 7.12 (d, 
J=8.4, 2.4 Hz, 1H), 7.07 (s, 1H), 6.94 (s, 1H), 5.83 (s, 1H), 5.7 (q, J= 12 Hz, 4H), 5.22 (s, 
1H), 5.17 (t, J=9.2 Hz, 2H), 5.10 (d, J=10.4 Hz, 1H), 4.82 (q, J=8.8 Hz, 3H), 4.43 (t, J=16 
Hz, 2H), 4.22 (dd, J=11.6 Hz, 10 Hz, 1H), 3.99 (d, J=3.6 Hz, 1H), 3.87 (s, 3H), 2.85 (m, 
J=18, 5H), 2.50 (m, J=25.6, 5H), 2.00 (dd, J=8.8 Hz, 1H) 1.91 (t, J=6.4 Hz, 2H), 1.50 (s, 
1H), 1.29 (d, 1H), 1.2 (t, J=14.8 Hz, 2H), 1.14 (dd, J=2.4 Hz, 1H) 0.96 (s, 12H). 
The single peak at 9.94 ppm shows the carbonyl. The quinoxaline group is in the 7.8-7.0 
ppm region. The range of peaks between 6.0-4.0 ppm show the additional Hydrogen on the 
carbamate, the esters, and double bonds. The peaks between 3.0-2.0 ppm are the sulfone. At 
approximately 2.0 ppm are the peaks for the ketones, and in the 2.0-1.0 ppm region are the 
remaining alkanes. This spectrum provides evidence of the locations of Hydrogen on the final 
compound and confirms the predicted structure.  
 
 
 
 
 
 
 
 
 
 
 
Conclusions  
The goal of this project was to synthesize the linear structure of the MK-5172 HCV drug, 
and modify the functional groups in order for it to fit better within the substrate envelope of 
HCV and minimize vulnerability to drug resistance. Past studies have shown HCV drugs without 
a side chain ring to be more adaptable in fighting the mutant variants. As a result of this project a 
new MK-5172 derivative was developed, and the compound is predicted to produce more 
efficient results against both the virus itself and its mutant variants. The derivative is smaller than 
the original drug, and is therefore predicted to fit in the substrate envelope and protect more 
proficiently against drug resistance.  
 The synthesis plan was developed for this drug in order to produce the most efficient 
yields, and the results of the synthesis show this. These steps provided consistent yields and, 
after further research of this drug and its variants, will allow for development on a large scale for 
treating HCV. In future development of the drug, different variations to the modified side groups 
is recommended, which may allow for better fitting in the substrate envelope and increase the 
inhibitor’s effectiveness. Following the current synthesis plan will provide the most efficient 
results, but it is recommended that step 5 is completed before steps 3 and 4, which will provide 
the intermediate used in step 7, (2S,4R)-Methyl 4-((3-ethyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidine-2-dicarboxylate. This synthesis showed steps 7 and 8 consistently gave more 
products, which will affect the development if the drug is to be produced on a larger scale. The 
current plan for the new MK-5172 derivate also results in the expected compounds without 
impurities. This was observed by the visible spots on the TLC tests, and the low amount of 
impurities seen in the NMR spectra of the products in Figures 7-13. 
 The Hepatitis C virus continues to affect the global population, and while current 
treatments are effective at combatting its symptoms and complications, there are still many 
severe side effects associated with them. HCV’s rapid mutations and drug resistance rates also 
make it increasingly difficult to treat. The continued development of new drugs, like MK-5172, 
will play a crucial role in combatting this virus and others like it. Researching new derivatives 
can result in greater drug effectiveness against HCV, and potentially a vaccine to prevent any 
further spread of the virus. The research should also focus on treating the different genotypes that 
have been identified, in an effort to combat the virus as a whole, and not just one variant. As new 
drugs are developed, researchers should explore exchanging functional groups on pre-existing 
drugs, like the ones seen in this project. Continued development of these new derivatives or new 
compounds will help to combat drug resistance, and are able to fit in the substrate envelope and 
bind to the NS3/4A proteins. It is the hope that in finding a solution to HCV, researchers will be 
able to use their information to treat other viruses, such as HIV, in an attempt to eliminate them 
and the diseases they cause.  
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Figures  
 
 
 
 
 
 
 
 
Figure 1: This figure represents a graphical representation of the major causes of HCV infection. Information obtained from: 
http://www.cdc.gov/hepatitis/Statistics/index.htm 
 
 
 
 
 
 
Figure 2: This figure shows the global estimated prevalence of Hepatitis C Virus based on regions as of 2011. The darker regions 
represent higher percentages Graphic from: http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-
to-travel/hepatitis-c.htm 
 
60% 
15% 
10% 
5% 
10% 
Sources of Infection for HCV 
Injection/Drug Use Sexual Transmission Blood Transfusion Other Unknown
 Figure 3: The chemical structures of the HCV NS3/4A protease inhibitors. Telaprevir, danoprevir, vaniprevir and MK-5172 are 
some of the protease inhibitors in development. Telaprevir, which is approved for clinical use, is an acyclic ketoamide inhibitor 
that forms a reversible, covalent bond with the protease. Danoprevir, currently in phase II clinical trials, is a non-covalent acyl 
sulfonamide inhibitor with a P1–P3 macrocycle. Vaniprevir and MK-5172 are also non-covalent acyl sulfonamide inhibitors, but 
contain P2–P4 macrocycles. Vaniprevir and MK-5172 differ in the construction of their P2 moieties: vaniprevir contains a 
carbamate linkage between the P2 proline and the isoindoline moiety, whereas MK-5172 contains a shorter ether linkage between 
its P2 proline and the quinoxaline moiety.14 
 
Figure 4: This figure shows the locations and variations of the P1-P3 and P2-P4 macrocycles for certain protease inhibitors. 
 
 Figure 5: This figure shows the MK-5172-linear structure. The side-groups marked “A” and “B” were modified for this project to 
determine if other chemical groups would increase enzymatic activity and effectiveness. The Chlorine in “A” was removed and 
an ethyl group was added in its place, and the t-butyl in “B” was removed and replaced with a cyclopentyl ring.  
 
 
Figure 6: This figure shows the new MK-5172 derivative. This new compound is predicted to produce more efficient results 
against both the virus itself and its mutant variants. By changing the functional groups on a molecule it can have positive or 
negative effects on inhibition, and it is the hope that this new derivative produces positive effects. 
 Figure 7: This figure shows the proton NMR spectra of the product in reaction 6. The peaks represent the locations of Hydrogen 
on the compound, and the solvent used is CDCl3. This product was synthesized through steps 1-6. This sample was 145mg and 
was combined with the product from reaction 8 in order to continue with the synthesis. 
 Figure 8: This figure shows the proton NMR spectra of the product in reaction 8. The peaks represent the locations of Hydrogen 
on the compound, and the solvent used is CDCl3. This product was synthesized starting with the intermediate starting material in 
reaction 7. This sample was 500mg and was combined with the product from reaction 6 in order to continue with the synthesis. 
the entire drug. 
 
 Figure 9: This figure shows the proton NMR spectra of the product in reaction 11. The peaks represent the locations of Hydrogen 
on the compound, and the solvent used is CDCl3. 
 
 Figure 10: This figure shows the proton NMR spectra of the final compound. The structure of the compound can be seen in 
Figure 5. The peaks represent the locations of Hydrogen on the compound, and the solvent used is CDCl3. 
 
 Figure 11: This figure shows the proton NMR spectra of the final compound within the range of 0.5 ppm to 3.0 ppm. The 
structure of the compound can be seen in Figure 5. The highlighted peaks represent the locations of Hydrogen on the compound, 
and the solvent used is CDCl3. 
 
 Figure 12: This figure shows the proton NMR spectra of the final compound within the range of 6.0 ppm to 3.0 ppm. The 
structure of the compound can be seen in Figure 5. The highlighted peaks represent the locations of Hydrogen on the compound, 
and the solvent used is CDCl3. 
 
 Figure 13: This figure shows the proton NMR spectra of the final compound within the range of 10.5ppm to 6.0ppm. The 
structure of the compound can be seen in Figure 5. The highlighted peaks represent the locations of Hydrogen on the compound, 
and the solvent used is CDCl3. 
